New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:50 EDTISISIsis Pharmaceuticals price target raised to $51 from $43 at BMO Capital
BMO Capital raised its price target on Isis as the firm expects the company to report favorable data for its ISIS-SMN-Rx treatment. The firm also expects interest in the company's other antisense oligonucleotide programs for neurodegenerative conditions to increase. It keeps an Outperform rating on the shares.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
18:04 EDTISISIsis Pharma granted FDA orphan status for treatment of familial chylomicronemia
Subscribe for More Information
08:58 EDTISISIsis Pharmaceuticals shares not reflecting SMA data, says Needham
Subscribe for More Information
June 22, 2015
07:01 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx in Phase 2 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use